An Exploratory Study to Evaluate Attention Biases in Adults With Multi
An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer
We could not find results for this trial
What it found
We found no results in the registry or in papers.
This trial finished 2 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- CT-100-D-004-A
- CT-100-D-004-B
What it measured
Main measures
Change in Patient Reported Outcomes
Baseline to Week 4
Quality of life (reported by participants)
Other measures (6)
Change in Pain Severity and Pain Interference
Baseline to Week 4
PainChange in Pain Catastrophizing Scale
Baseline to Week 4
PainChange in indication-specific measures MS
Baseline to Week 4
Thinking and memoryChange in indication-specific measures Cancer
Baseline to Week 4
Thinking and memoryProportion of participants with an improvement
Baseline to Week 4
Engagement with Study App
Baseline to Week 4
Who could take part
MS (type not specified) · 22 to 65
Show the full criteria
Inclusion criteria
* A participant will be eligible for entry into the study if all of the following criteria are met: 1. Fluent in written and spoken English, confirmed by ability to read, understand, and sign the informed consent form 2. Lives in the United States 3. Adult between 22 and 65 years old 4. Meets indication-specific including criteria, as reported by the study participant with adequate clinical documentation (to be provided to the study team upon request) 5. Has an active email address and is willing and able to receive and respond to email messages 6. Has access to an internet connection during the study duration 7. Has an active PayPal account to receive study compensation, or is willing to create one 8. Willing and able to comply with study protocol and assessments 9. Is the sole user of an iPhone with an iPhone operating system (iOS) version 14 or later or a smartphone with an Android operating system (OS) version 10 or later for the duration of the study 10. Is willing and able to receive Short Message Service (SMS) text messages and notifications on their smartphone 11. Has access to operating headphones
Exclusion criteria
* A participant will not be eligible for study entry if any of the following criteria are met: 1. Visual, dexterity or cognitive deficit so severe that it precludes the use of an App-based reaction time-based activity per investigator judgment 2. Severe psychiatric disorder involving a history of psychosis (e.g., schizophrenia, bipolar disorder, severe personality disorders) 3. Psychiatric hospitalization in the past 6 months 4. Participation in any research study (including studies on psychotherapy, mindfulness, cognitive training or pharmacological treatment) during the past 3 months 5. Initiation or change in primary disease-specific medication within 30 days prior to entering the study 6. Planning the introduction of new therapies (including studies on psychotherapy, mindfulness, cognitive training or pharmacological treatment) during the study duration (6 weeks) 7. Anticipating a change in current pharmacological or psychotherapy treatment regimen during the study period (6 weeks) 8. Self-reported substance use disorder within the past 1 year 9. Severe neurological disorders impairing brain function (e.g., previous stroke, dementia, primary brain function, brain metastases, Alzheimer's disease, Parkinson's disease, history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities) 10. Mild, moderate, severe or profound unilateral or bilateral hearing loss
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics. One class of CT-100 components are Digital Neuro-activation and Modulation (DiNaMo) components. DiNaMo components target key neural systems (including but not limited to systems related to sensory-, perceptual-, affective-, pain-, attention-, cognitive control, social- and self-processing) to optimally improve a participant's health.
Loading reviews and guidelines…
History
Started
Oct 2023
Main results due
Apr 2024
Finished
May 2024